secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001104659-25-056421
Event type: regulatory
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing
--------------------------------------------------------------------------------

- Received Nasdaq notice on May 29, 2025, for non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q.
- Filed the overdue Form 10-Q for Q1 2025 on June 2, 2025.
- Nasdaq confirmed on June 3, 2025, that the company regained compliance; matter is closed.
- Pre-clinical biotech (LIMN) focuses on immune-modulating cancer therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/0001104659-25-056421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925056421/tm2517129d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-056421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer